Advertisement

Topics

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

2014-07-24 14:01:10 | BioPortfolio

Summary

The purpose of this study is to demonstrate that different CYD Dengue vaccine lots manufactured using the same method and in the same location but at different times produce an equivalent immunological response.

Primary Objective

- To demonstrate that three different Phase III lots of CYD Dengue vaccine induce an equivalent immune response in terms of post-Dose 3 geometric mean titers (GMTs) against the four parental serotypes.

Secondary Objectives:

- To demonstrate that Phase II and pooled Phase III lots of CYD Dengue vaccine induce an equivalent immune response in terms of post-Dose 3 GMTs against the four parental serotypes.

- To describe the safety (in terms of solicited injection site and systemic reactions and unsolicited adverse events) of the CYD Dengue vaccine in all subjects after each dose.

Description

All subjects will receive 3 doses of their assigned vaccine or placebo and will provide blood samples at defined timepoints for flavivirus status and immunogenicity assessment. Reactogenicity data will be collected in all subjects after each dose and throughout the study.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Conditions

Dengue Fever

Intervention

Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus, Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus, Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus, Live, attenuated, recombinant dengue serotypes 1, 2, 3

Location

Adelaide
Australia
SA 5000

Status

Not yet recruiting

Source

Sanofi-Aventis

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-24T14:01:10-0400

Clinical Trials [1317 Associated Clinical Trials listed on BioPortfolio]

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

The purpose of this study is to investigate the potential for co-administration of the first dose of CYD Dengue vaccine with childhood vaccination. Primary Objectives: - To desc...

Tetravalent Chimeric Dengue Vaccine Trial

The purpose of this study is to test the safety and immune response to a live attenuated dengue vaccine that could protect people against all 4 types of dengue virus. Live attenuated means...

A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants

The main target populations for the tetravalent live attenuated dengue virus vaccine are indigenous populations, especially infants less than 2 years old, residing in areas of the world en...

A Phase II Trial of a WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

This descriptive study will evaluate the safety and immunogenicity of 3 different formulations of the WRAIR dengue vaccine compared to a placebo.

Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine

Infection with dengue viruses is the leading cause of hospitalization and death in children in many tropical Asian countries, and the development of a dengue vaccine is a top health priori...

PubMed Articles [6837 Associated PubMed Articles listed on BioPortfolio]

Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding.

We assessed replication and excretion of the live attenuated tetravalent dengue vaccine (CYD-TDV) into biological fluids following vaccination in dengue-naive adults in Australia.

Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.

Dengue virus (DENV) is one of the most widespread arboviruses. The four DENV serotypes infect about 400 million people every year, causing 96 million clinical dengue cases, of which approximately 500'...

Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice.

We describe novel plasmid DNA that encodes the full-length Japanese encephalitis virus (JEV) genomic cDNA and launches live-attenuated JEV vaccine in vitro and in vivo. The synthetic cDNA based on the...

A quinoline compound inhibits the replication of dengue virus serotypes 1-4 in Vero cells.

The global occurrence of dengue, a mosquito-borne viral disease caused by four distinct dengue viruses (DENV-1, -2, -3 and -4), is reported to have increased ~30-fold in the last fifty years, causing ...

Live Attenuated Influenza Vaccination Prior To Age 3 Years and Subsequent Development of Asthma: A 14-Year Follow-Up Study.

Live-attenuated influenza vaccines (LAIVs) are not licensed in children

Medical and Biotech [MESH] Definitions

Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.

A species of ENTEROVIRUS which is the causal agent of POLIOMYELITIS in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.

A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.

A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)

A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.

More From BioPortfolio on "Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Searches Linking to this Trial